STAT+: Invitae’s new CEO on why the genetic testing firm stopped chasing ‘volume at all costs’
SAN FRANCISCO — Invitae, a Bay Area genetic testing company with a mission to use…
Category: JPM23
Virtual Event: “JPM Recap, Live!” 2023
Editor’s Note: A live stream of the event will be embedded below at 1:00 PM…
STAT+: Biotech startups are hungry for dollars. Here’s what one pharma executive was looking for at JPM
Marianne De Backer’s iPhone calendar is a solid block of green. De Backer, the head…
STAT+: Regeneron executive George Yancopoulos admits some regret, but ‘I don’t apologize’
SAN FRANCISCO — George Yancopoulos isn’t apologizing. The president and chief scientist of Regeneron was…
#JPM23 in review, the year ahead, & the merits of Miami
What happened at biotech’s big reunion? Will this year be better than the last? And…
Opinion: A lesson from JPM: Too many digital front doors in health care lead to nowhere
Top health care leaders braved rain, hail, and flash flood warnings at this year’s J.P….
STAT+: FDA’s Califf says congressional report on Aduhelm controversy contained “no surprises”
SAN FRANCISCO – U.S. Food and Drug Administration commissioner Robert Califf doesn’t disagree with the…
STAT+: New Biogen CEO: New drug launches, more cost cuts, but no ‘radical left turns’ needed
SAN FRANCISCO — In some of his first extended comments since taking over as Biogen’s…
STAT+: BioMarin executives express confidence around hemophilia gene therapy
For years, BioMarin CEO Jean-Jacques “J.J.” Bienaime has been saying that Roctavian — the company’s…
STAT+: The health care providers and insurers we’re watching at JPM23 — and why
Hospitals, health insurers, and other provider-related companies are returning in person to the J.P. Morgan…
STAT+: Money troubles and M&A: What’s on biotech insiders’ minds ahead of a not-so-celebratory JPM week
SAN FRANCISCO — What should be a triumphant return to the global biotech industry’s biggest…